Improvements in health-related quality of life with esketamine nasal spray versus quetiapine extended release

Andreas Reif*: Affiliation:
University Medical Centre Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt am Main, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany;
Bernhard T. Baune: Affiliation:
Department of Psychiatry, University of Münster, Münster, Germany; Department of Psychiatry, The University of Melbourne, Melbourne, Australia;
Jozefien Buyze: Affiliation:
Johnson & Johnson, Beerse, Belgium;
Anthony J. Cleare: Affiliation:
Institute of Psychiatry, Psychology & Neuroscience, King’s College London, London, UK;
Shaun Johnson: Affiliation:
GAMIAN-Europe, Brussels, Belgium;
Yerkebulan Kambarov: Affiliation:
Johnson & Johnson, Beerse, Belgium;
Nigel Olisa: Affiliation:
GAMIAN-Europe, Brussels, Belgium;
Falk Schuster: Affiliation:
Independent consultant, Leipzig, Germany;
Christian von Holt: Affiliation:
Johnson & Johnson, Neuss, Germany;
Tamara Werner-Kiechle: Affiliation:
Johnson & Johnson, Neuss, Germany;
Eduard Vieta: Affiliation:
Institute of Neuroscience, University of Barcelona, Hospital Clinic, IDIBAPS, CIBERSAM, Barcelona, Spain
*: Corresponding author:Correspondence to: Andreas Reif, Email: reif@med.uni-frankfurt.de

Article contents

Abstract

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

esketamine health-related quality of life treatment resistant depression quetiapine

Information

Type: Research Article
Information: European Psychiatry , Accepted manuscript , pp. 1 - 31

DOI: https://doi.org/10.1192/j.eurpsy.2025.10123 [Opens in a new window]
Creative Commons: This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.